Artificial intelligence is changing how scientists discover new medicines.
Agemica AI drug discovery combines artificial intelligence, biology, and data science to find new ways to treat cancer and age-related diseases.
While many biotech companies focus on one disease at a time, Agemica takes a broader approach. The company studies the biology of aging, which is a major factor behind cancer and many chronic diseases.
As a Propel(x) portfolio company, Agemica is building AI-powered tools to support the future of healthcare and longevity research.
How Agemica Uses AI for Drug Discovery
Creating new medicines is a long and difficult process. Scientists often spend years testing potential treatments before they reach patients.
Agemica uses artificial intelligence to make this process faster and more efficient.
The company’s AI platform studies large amounts of biological data. It helps researchers find new drug candidates and identify possible treatments that may have been missed using traditional methods.
Through AI drug discovery, Agemica aims to:
- Find new treatment opportunities
- Identify promising drug candidates
- Study how different therapies interact
- Develop solutions for complex diseases
This approach could help researchers reduce the time and cost needed to develop new medicines.
Fighting Cancer Through AI-Powered Research
Cancer is one of the biggest healthcare challenges worldwide. Finding new treatments requires a deep understanding of how cancer develops and spreads.
Agemica is using artificial intelligence to explore new cancer therapies and vaccine approaches.
The company recently announced several important milestones:
- AI-designed peptides from its universal cancer vaccine program showed tumor-shrinking activity across 13 cancer types in ex vivo studies.
- Seven proprietary drug combinations showed positive combined effects across 12 cancer types.
- Agemica completed the design of its vaccine platform and is preparing for animal studies using humanized mouse models, starting with pancreatic cancer.
These achievements highlight the potential of AI to support faster and more targeted cancer research.
Exploring the Science of Aging
Aging is one of the biggest risk factors for many diseases, including cancer.
Instead of only treating individual conditions, Agemica is studying the biological changes linked to aging.
The company uses AI to analyze complex biological information and search for new ways to improve health outcomes as people age.
This work places Agemica at the intersection of:
- Artificial intelligence
- Biotechnology
- Longevity research
- Healthcare innovation
The Future of AI in Healthcare
Artificial intelligence is opening new possibilities in medicine.
AI can help scientists analyze large datasets, discover new patterns, and develop better treatment options.
Companies like Agemica show how technology and biology can work together to solve difficult healthcare problems.
By combining AI with scientific research, Agemica aims to create new approaches for treating diseases linked to aging and cancer.
Advancing the Next Generation of Biotechnology
Agemica was founded by Dr. Ronjon Nag, CEO and Co-Founder, and Yasaman Kalantar Motamedi, CTO and Co-Founder.
The team brings together expertise in artificial intelligence, biotechnology, and scientific innovation.
At Propel(x), we are excited to follow Agemica’s continued progress as it develops AI-powered solutions for healthcare and longevity.
Discover more deep technology companies working on breakthrough innovations by registering on Propelx.com.
